Trial Search Results

Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers

This pilot clinical trial studies the use of integrin alpha-v-beta [18F]-R01-MG-F2 positron emission tomography (PET)/computed tomography (CT) in measuring response in patients with pancreatic cancer and healthy volunteers. Integrins, such as integrin alpha-v-beta [18F]-R01-MG-F2, are a family of membrane receptors that are overexpressed and attaches to various proteins which sense and respond to contact events that occur at the cell surface and may improve early detection of pancreatic cancer and improve patient selection for anti-integrin alpha-v-beta 6 therapy.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Sanjiv Sam Gambhir

Collaborator: National Cancer Institute (NCI)

Stanford Investigator(s):

Intervention(s):

  • Procedure: Computed Tomography
  • Other: Laboratory Biomarker Analysis
  • Procedure: Positron Emission Tomography
  • Drug: [18F]FP-R01-MG-F2
  • Drug: [18F]-FDG

Phase:

N/A

Eligibility


Inclusion Criteria:

   - HEALTHY VOLUNTEER INCLUSION CRITERIA:

      - Must have no known medical problems and have had a full medical exam within 6
      months of the study

      - Must understand and voluntarily have signed an Informed Consent after its
      contents have been fully explained

   - PANCREATIC CANCER PATIENT INCLUSION CRITERIA:

      - Provides written informed consent

      - Diagnosed with pancreatic cancer and scheduled to undergo surgery

      - Able to remain still for duration of each imaging procedure (about one hour)

Exclusion Criteria:

   - HEALTHY VOLUNTEER EXCLUSION CRITERIA:

      - Pregnant or nursing

   - PANCREATIC CANCER PATIENT EXCLUSION CRITERIA:

      - Participant is pregnant or breast-feeding

      - Patients with contraindications for PET/CT or who cannot complete a PET/CT scan

      - Patients not able to comply with the study procedures

      - Patients with serious uncontrolled concurrent medical illness that would limit
      compliance with study requirements

      - Eastern Cooperative Oncology Group (ECOG) performance status (PS) > 2

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Krithika Rupnarayan
650-736-0959
Recruiting